The Silent Brain Disease Most People Have Never Heard Of — and How It Quadruples Dementia Risk

A protein buildup in the blood vessels of the brain, often undetected for years, may be one of the strongest risk factors for dementia ever identified. A large-scale study of nearly two million older Americans has found that cerebral amyloid angiopathy — an incurable condition affecting up to a quarter of adults over 50 — is associated with a fourfold increase in dementia risk within five years [1][2].

The findings, presented at the American Stroke Association's International Stroke Conference in February 2026, raise urgent questions about screening, prevention, and the limits of what medicine can offer patients diagnosed with a condition that has no cure [1].

What the Study Found

Researchers led by Samuel S. Bruce, an assistant professor of neurology at Weill Cornell Medicine, analyzed Medicare health records for 1,909,365 adults aged 65 and older, spanning 2016 to 2022 [1][2]. Among them, 752 had been clinically diagnosed with cerebral amyloid angiopathy, or CAA — a condition in which amyloid-beta proteins accumulate in the walls of small blood vessels in the brain, gradually weakening them [1].

The central finding: 42% of people with CAA received a dementia diagnosis within five years, compared to just 10% of those without the condition [1][2][3]. That translates to a 4.3-fold increase in risk for CAA patients who had never experienced a stroke, and a 4.5-fold increase for those with both CAA and a history of stroke [1]. For comparison, having a stroke alone — without CAA — raised dementia risk by 2.4 times [1].

"Many people with CAA develop dementia; however, so far, clinicians haven't had clear, large-scale estimates on how often and how quickly dementia progresses," Bruce said [1].

Perhaps the most striking element of these results is that stroke did not meaningfully alter the trajectory. The dementia risk for CAA patients without stroke history (4.3x) was nearly identical to those with stroke (4.5x) [1][2]. This suggests that the amyloid protein deposits themselves — not just the hemorrhages they can cause — are driving cognitive decline through independent mechanisms.

What Is Cerebral Amyloid Angiopathy?

CAA is a cerebrovascular disorder in which amyloid-beta, the same protein implicated in Alzheimer's disease, deposits along the walls of small and medium-sized arteries, arterioles, and capillaries in the brain [4][5]. Over time, these deposits weaken vessel walls, increasing vulnerability to bleeding and reducing the brain's ability to clear waste products [4].

The condition is often called "silent" because it can progress for years or decades without noticeable symptoms. Diagnosis typically requires MRI or PET imaging, and definitive confirmation has historically required postmortem examination [5][6]. This diagnostic difficulty means prevalence estimates vary widely depending on the method used.

A 2022 systematic review and meta-analysis published in Alzheimer's & Dementia found that pathology-based CAA prevalence in the general population is approximately 23%, rising to 48% in patients with Alzheimer's disease [6]. Autopsy studies show prevalence climbing steeply with age: 5–9% in people aged 60–69, and 43–58% in those over 90 [5][6]. In the Medicare population studied by Bruce's team, clinically diagnosed CAA appeared in only 0.04% of beneficiaries — a figure that likely represents severe underdiagnosis given the imaging and autopsy-based estimates [1][5].

Between 23% and 29% of adults over 50 have moderate to severe CAA, according to the Cleveland Clinic [3]. If even a fraction of these individuals face the elevated dementia risk identified in the study, the public health implications are substantial.

Source: American Heart Association / Bruce et al. 2026

Data as of Feb 6, 2026CSV

The Biological Mechanism: One Peptide, Two Pathways

CAA and Alzheimer's disease share a common molecular culprit — amyloid-beta — but the proteins deposit in different locations. In Alzheimer's, amyloid accumulates in the brain tissue itself, forming plaques between neurons. In CAA, it collects in blood vessel walls [4][7].

The two conditions frequently coexist. Steven M. Greenberg, a professor of neurology at Harvard Medical School and director of the Hemorrhagic Stroke Research Program at Massachusetts General Hospital, described the overlap as "a potent 1-2 punch" [1][8].

"Diseases of the brain's small blood vessels are major contributors to dementia," Greenberg said. "This is especially true for CAA, which often occurs together with Alzheimer's disease" [1].

The biological pathway from CAA to cognitive decline involves several interacting mechanisms [4][7][9]:

• Vascular damage: Amyloid deposits weaken blood vessel walls, leading to microbleeds, larger hemorrhages, and small infarcts (areas of tissue death from interrupted blood supply) [4].
• Blood-brain barrier breakdown: The deposits compromise the blood-brain barrier, a protective membrane that normally prevents harmful substances from entering brain tissue. This allows inflammatory molecules and plasma proteins to leak into the brain [9].
• Neuroinflammation: The immune system responds to vascular amyloid deposits by triggering chronic inflammation, which damages surrounding neurons and accelerates neurodegeneration [9][10].
• Impaired waste clearance: The brain normally clears amyloid-beta and other waste through perivascular drainage pathways along blood vessels. CAA disrupts these pathways, creating a self-reinforcing cycle: more amyloid deposits, less clearance, further accumulation [4][7].

Researchers believe these mechanisms can cause cognitive impairment independently of stroke or Alzheimer's plaques, which aligns with the Bruce study's finding that CAA raised dementia risk nearly as much without stroke as with it [1][4].

How CAA Compares to Other Dementia Risk Factors

The 2024 Lancet Commission on dementia prevention identified 14 modifiable risk factors that together account for approximately 45% of dementia cases worldwide [11][12]. These include hearing loss and high LDL cholesterol (each responsible for about 7% of cases), low education and social isolation (about 5% each), plus hypertension, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol, traumatic brain injury, air pollution, and untreated vision loss [11][12].

The APOE ε4 gene variant — the strongest known genetic risk factor — roughly triples or quadruples dementia risk for carriers of two copies [13]. A 2025 study in Nature Medicine found that the lifetime risk of dementia after age 55 is 42% overall, with rates reaching 45–60% in women, Black adults, and APOE ε4 carriers [13].

CAA's fourfold risk increase places it in the same range as carrying two APOE ε4 alleles, and well above individual modifiable risk factors like hypertension or diabetes [1][11]. However, direct comparison is complicated. The Lancet Commission's modifiable factors are expressed as population attributable fractions — the percentage of all dementia cases that could be prevented by eliminating the risk factor — while the Bruce study reports relative risk among diagnosed individuals. CAA's attributable fraction in the population remains uncertain, partly because the true prevalence of clinically significant CAA is unknown [1][5][6].

Still, Greenberg's characterization of CAA plus Alzheimer's as a "1-2 punch" suggests that for individuals who have both — and autopsy data indicate nearly half of Alzheimer's patients do — the combined effect on dementia risk is substantial [1][6][8].

Who Is Most Affected?

The Bruce study's demographics reflected the Medicare population: average age 73, 54% women, 82.4% white, 7.3% Black, and 10.3% other racial and ethnic groups [1][2]. These proportions limit what the study can say about differential risk across racial and ethnic groups, particularly since CAA diagnosis rates may vary based on access to neuroimaging.

Age is the dominant risk factor for both CAA and dementia independently. Dementia prevalence rises from about 5% among people aged 65–74 to 33% among those 85 and older in the United States [13][14]. CAA follows a similar trajectory, with autopsy-confirmed prevalence reaching 43–58% in people over 90 [5][6].

Source: World Bank

Data as of Mar 21, 2026CSV

This convergence means the oldest adults face compounded risk. A person in their late 80s or 90s who has both CAA and other risk factors — APOE ε4 status, hypertension, diabetes — is facing several overlapping drivers of cognitive decline simultaneously. The 2024 Lancet Commission found that having four or more chronic conditions raised dementia risk by 61% compared to having zero or one [11][15].

Women may face disproportionate risk for reasons that remain under investigation. They have higher lifetime dementia risk than men (partly due to longer life expectancy), and some evidence suggests sex differences in amyloid metabolism and vascular aging patterns [13].

The Treatment Gap: Incurable but Not Unmanageable

There is no cure for CAA, and no approved therapy that can halt or reverse the protein deposits [16][17]. This distinguishes it from many of the Lancet Commission's modifiable risk factors, where evidence-based interventions — hearing aids, blood pressure medication, cholesterol management — can directly reduce risk [11].

Current clinical management of CAA focuses on reducing secondary harms [16][17]:

• Blood pressure control: Hypertension increases the risk of hemorrhagic stroke in CAA patients, so aggressive blood pressure management is standard practice.
• Avoiding blood thinners: Anticoagulant medications increase bleeding risk and are generally contraindicated in patients with known CAA.
• Lifestyle modifications: Exercise, smoking cessation, and heart-healthy diet may slow vascular damage, though direct evidence in CAA-specific populations is limited.
• Cognitive monitoring: Bruce's team emphasized the importance of proactive screening for cognitive changes after a CAA diagnosis to identify and address decline early [1].

Research into disease-modifying treatments is underway but remains in early stages. Experimental approaches include targeting amyloid-beta production, enhancing the brain's natural waste-clearance mechanisms (particularly through sleep-related vascular oscillations), and immunosuppressive treatment for the subset of patients who develop CAA-related inflammation [16][17].

The question of how much risk reduction is achievable through these secondary measures remains unanswered. No clinical trial has demonstrated that managing CAA-associated risk factors reduces the subsequent rate of dementia in these patients specifically. The evidence is extrapolated from general cardiovascular and dementia prevention research [11][16].

Methodological Limitations

The study has not yet been peer-reviewed. It was presented as a research abstract at the International Stroke Conference 2026, and the American Heart Association noted that findings are "considered preliminary until published as a full manuscript in a peer-reviewed scientific journal" [1][2].

Several methodological issues warrant caution:

Diagnostic codes, not imaging: The researchers used administrative billing codes from Medicare claims to identify CAA cases, which Bruce acknowledged are "an imperfect proxy for clinical diagnoses" [1]. The study lacked access to MRI or other imaging data that would allow more rigorous assessment. This likely means the 752 diagnosed cases represent only the most obvious or severe instances of CAA, potentially inflating the apparent risk.

Retrospective design: The analysis looked backward through existing health records rather than following patients prospectively. This limits the ability to control for confounding variables — factors that might independently contribute to both CAA diagnosis and dementia.

Low diagnostic rate: Only 0.04% of the study population had a CAA diagnosis, far below prevalence estimates from autopsy and imaging studies [1][5][6]. The diagnosed group may differ systematically from undiagnosed CAA patients, making it difficult to generalize the 4.3x risk figure to the broader population of people who have CAA but don't know it.

Lack of diversity: The study population was 82.4% white, limiting conclusions about risk in other racial and ethnic groups [1].

No replication studies using similar methodology have been published. The relationship between CAA and cognitive decline has been documented in smaller clinical studies and autopsy series [4][5][7], but the specific risk magnitude reported here — a fourfold increase within five years — awaits independent confirmation.

The Ethics of Disclosing Incurable Risk

Telling patients they have a condition that raises their dementia risk fourfold, with no available cure, raises difficult ethical questions.

A 2025 paper in Alzheimer's & Dementia examined the ethics of disclosing iatrogenic CAA (a form transmitted through certain medical procedures) and found that disclosure is warranted based on professional responsibility to facilitate autonomous decision-making, even when "limited clinical benefits" exist [18]. The authors identified three core questions: Should clinicians disclose their CAA suspicion? Should they recommend the additional tests needed for diagnosis? Should they proactively notify asymptomatic at-risk individuals? [18]

Research also shows that CAA patients already face elevated rates of neuropsychiatric symptoms. A study in the Journal of the American Heart Association found that 48.8% of CAA patients experienced depression or dysphoria, 37.2% had irritability, and 32.6% reported anxiety [19]. Adding a fourfold dementia risk disclosure to this existing burden requires careful clinical judgment.

On the other hand, early detection could motivate adoption of brain-protective behaviors — blood pressure management, physical activity, cognitive engagement — and enable patients and families to plan for possible future needs. The 2024 Lancet Commission's finding that 45% of dementia is attributable to modifiable risk factors suggests meaningful room for risk reduction even when one non-modifiable factor is present [11][12].

No published data directly measure whether disclosing CAA-related dementia risk leads to net positive or negative behavioral changes. The field is borrowing from analogous debates around APOE ε4 genetic testing, where studies have shown that most patients cope well with risk information and some make beneficial lifestyle changes, though a minority experience sustained distress [12].

What Comes Next

The Bruce study provides the largest population-level estimate to date of how strongly CAA is associated with subsequent dementia. Its central contribution is quantifying something neurologists have long observed in clinical practice: that patients with visible amyloid deposits in their brain blood vessels tend to decline cognitively at alarming rates.

But the gap between observational association and clinical action remains wide. The study cannot establish that CAA causes dementia in any given individual — it may be that both CAA and dementia are downstream consequences of shared aging processes, or that the diagnosed CAA cases represent a subset with particularly aggressive amyloid pathology.

What is clear is that the aging of populations worldwide — the share of people aged 65 and older has risen from 14.3% to 17.4% in the United States alone between 2015 and 2023 [20] — means the absolute number of people with both CAA and dementia will grow substantially in coming decades. Whether that growth is met with better screening tools, disease-modifying therapies, or simply earlier conversations between doctors and patients about cognitive risk will depend on research that is, for now, still in its early stages.

As Greenberg put it: "Diseases of the brain's small blood vessels are major contributors to dementia" [1]. The question is no longer whether CAA matters. It's what to do about it.